Barclays’s Galmed Pharmaceuticals GLMD Stock Holding History

Barclays’s Portfolio GLMD Stock Details GLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Hold	0	–	-$2K	–	7123
2018 Q4	–	Hold	0	–	–	–	6712
2018 Q3	–	Sell	-1	Closed	-$18K	–	7218
2018 Q2	$18K	Buy	+1	New	+$11.6K	﹤0.01%	6235
2016 Q2	–	Sell	-2	Closed	-$10K	–	6422
2016 Q1	$10K	Buy	+2	New	+$15.7K	﹤0.01%	5466

Other funds holding GLMD

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Ibex Investors Denver, Colorado $194M AUM 23.58% 1-Year Est. Return

MIH

Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return

FMBTD

First Midwest Bank Trust Division Joliet, Illinois $777M AUM 29.48% 1-Year Est. Return

PAWC

P.A.W. Capital Greenwich, Connecticut $131M AUM 35.16% 1-Year Est. Return

Barclays's GLMD Position: Q1 2019 in Review

Barclays held its Galmed Pharmaceuticals (GLMD) position steady in Q1 2019 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #7123.

Barclays first reported a position in GLMD in Q1 2016 and has held it in 2 quarters since. The position peaked at $18K in Q2 2018. 29 funds tracked by Wall St. Rank hold GLMD as of Q1 2019.

Barclays held 0 shares of Galmed Pharmaceuticals worth $0 as of Q1 2019.
Barclays left its Galmed Pharmaceuticals share count unchanged in Q1 2019.
Galmed Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q1 2019, its #7123 holding.
Barclays first reported a position in Galmed Pharmaceuticals in Q1 2016 and has held it in 2 quarters since.
Barclays's Galmed Pharmaceuticals position peaked at $18K in Q2 2018.
29 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q1 2019.

Based on Barclays's 13F filing for Q1 2019, filed 15 May 2019.